Impax Laboratories, Inc. (IPXL) Stake Held by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky continued to hold its position in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,200 shares of the specialty pharmaceutical company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Impax Laboratories were worth $319,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in IPXL. Quadrature Capital Ltd bought a new position in shares of Impax Laboratories during the fourth quarter worth $224,000. State of Wisconsin Investment Board bought a new position in shares of Impax Laboratories during the first quarter worth $1,577,000. Legato Capital Management LLC increased its position in shares of Impax Laboratories by 1,165.0% in the first quarter. Legato Capital Management LLC now owns 29,892 shares of the specialty pharmaceutical company’s stock worth $2,363,000 after buying an additional 27,529 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Impax Laboratories by 12.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,791,702 shares of the specialty pharmaceutical company’s stock worth $23,739,000 after buying an additional 194,694 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Impax Laboratories by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock worth $79,080,000 after buying an additional 276,765 shares in the last quarter. 83.57% of the stock is owned by hedge funds and other institutional investors.

Get Impax Laboratories Inc. alerts:

Impax Laboratories, Inc. (NASDAQ IPXL) opened at 18.45 on Friday. The company has a 50 day moving average of $17.60 and a 200 day moving average of $14.55. Impax Laboratories, Inc. has a 1-year low of $7.75 and a 1-year high of $27.29. The firm’s market capitalization is $1.33 billion.

Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business had revenue of $202.08 million for the quarter, compared to analysts’ expectations of $195.62 million. During the same period in the previous year, the business posted $0.21 EPS. The firm’s quarterly revenue was up 17.1% compared to the same quarter last year. On average, equities research analysts anticipate that Impax Laboratories, Inc. will post $0.70 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Impax Laboratories, Inc. (IPXL) Stake Held by Teachers Retirement System of The State of Kentucky” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/19/impax-laboratories-inc-ipxl-stake-maintained-by-teachers-retirement-system-of-the-state-of-kentucky-updated.html.

Several brokerages have recently commented on IPXL. BidaskClub cut shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Canaccord Genuity set a $19.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company set a $20.00 price objective on shares of Impax Laboratories and gave the company a “hold” rating in a report on Wednesday, August 9th. Zacks Investment Research cut shares of Impax Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $62.00 price objective (up previously from $10.00) on shares of Impax Laboratories in a report on Thursday, May 11th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $17.85.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

What are top analysts saying about Impax Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Impax Laboratories Inc. and related companies.